Another most common malignant haematological disease chronic myeloid leukaemia (CML), in most of which has BCR-ABL fusion protein, also has a high risk of myeloid progression even after treatment with tyrosine kinase inhibitors [11–14]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.